The hemodynamic effects of intraoperative injection of muromonab CD3.

Transplantation

Department of Anesthesiology, Oregon Health Sciences University, Portland 97201.

Published: August 1993

During anesthesia 5 mg of muromonab CD3 (OKT3), an anti-CD3 monoclonal antibody, was administered prophylactically to twelve patients undergoing cadaveric renal transplantation. Preoperatively, all patients were at or near their dry body weights. Methylprednisolone 500 mg on call to or in the operating room, azathioprine 2 mg kg-1 and diphenhydramine 50 mg were administered intraoperatively to reduce the probability and severity of reported effects of OKT3. After induction of anesthesia, the patients were monitored for changes in cardiovascular variables for up to 120 min after OKT3 administration. All patients had uneventful anesthetic courses. Analysis of variance showed no significant changes from pre-OKT3 administration in heart rate, mean blood pressure, mean pulmonary artery pressure, central venous pressure (CVP), pulmonary capillary wedge pressure (PCWP), and pulmonary vascular resistance (PVRI). CVP values were a reliable indicator of PCWP with the correlation coefficient of CVP to PCWP or r = 0.78 (P < 0.00005) and PCWP = .89 x CVP + 3.78. Cardiac index (CI) increased 22% at 105 min (P < 0.05). Systemic vascular resistance index (SVRI) decreased 21% at 105 min (P < 0.05). SVRI was increased 16% at 10 min post-OKT3 (P < 0.05). All of these statistically significant values were within acceptable clinical limits. Euvolemic cadaveric renal transplant recipients receiving prophylactic steroids and diphenhydramine may receive OKT3 in the operating room for induction immunosuppression without any appreciable risk of cardiovascular compromise.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00007890-199308000-00020DOI Listing

Publication Analysis

Top Keywords

muromonab cd3
8
cadaveric renal
8
operating room
8
vascular resistance
8
105 min
8
min 005
8
hemodynamic effects
4
effects intraoperative
4
intraoperative injection
4
injection muromonab
4

Similar Publications

Objectives: Despite their efficacy, some immunotherapies have been shown to induce immune-related adverse events, including the potentially life-threatening cytokine release syndrome (CRS), calling for reliable and translational preclinical models to predict potential safety issues and investigate their rescue. Here, we tested the reliability of humanized BRGSF mice for the assessment of therapeutics-induced CRS features in preclinical settings.

Methods: BRGSF mice reconstituted with human umbilical cord blood CD34 cells (BRGSF-CBC) were injected with anti-CD3 antibody (OKT3), anti-CD3/CD19 bispecific T-cell engager Blinatumomab, or VISTA-targeting antibody.

View Article and Find Full Text PDF

The future is on the way: β cell function preservation for type 1 diabetes.

Med

January 2024

Department of Endocrinology and Metabolism, National Clinical Research Center for Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China. Electronic address:

This phase 3 trial of PROTECT confirms the beneficial effects of teplizumab (anti-CD3 treatment) in type 1 diabetes and expands the indications from diabetes prevention (stage 2) to early treatment (stage 3). More efforts are needed to confirm the effects in the general population, with a higher dose, and with repeated dosing.

View Article and Find Full Text PDF

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition characterized by the irreversible destruction of the β cells of the pancreas, which leads to a lifelong dependency on exogenous insulin. Despite the advancements in insulin delivery methods, the suboptimal outcomes of these methods have triggered the search for therapies that may prevent or reverse the disease. Given the autoimmune aetiology of T1DM, therapies counteracting the immune-mediated destruction of the β-cells are the obvious target.

View Article and Find Full Text PDF
Article Synopsis
  • Amphiregulin (AREG) is a key ligand for the epidermal growth factor receptor (EGFR) that affects monocyte-induced cell death and T-cell responses in peripheral blood.
  • The study found that AREG reduces T-cell proliferation during stimulation and down-regulates costimulatory molecules on monocytes, indicating its role in modulating immune responses.
  • Additionally, AREG influences T-cell polarization, leading to an increase in IL-17-producing T cells, while maintaining the regulatory T cell proportion.
View Article and Find Full Text PDF

Objective: Systemic lupus erythematosus (SLE) patients are at risk during the COVID-19 pandemic, yet the underlying molecular mechanisms remain incompletely understood. This study sought to analyze the potential molecular connections between COVID-19 and SLE, employing a bioinformatics approach to identify effective drugs for both conditions.

Methods: The data sets GSE100163 and GSE183071 were utilized to determine share differentially expressed genes (DEGs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!